Press Room

AAPS 2016

Start
Sunday, November 13, 2016 - 00:00
End
Thursday, November 17, 2016 - 00:00
Location: Denver, United States
Booth Number: 1627
spray drying pharmaceutical industry USA | Hovione

Hovione will be present at the 2016 AAPS Annual Meeting in the Colorado Convention Center in Denver.

A set of seven (7) posters will be exhibited in the poster session. If you are attending AAPS, look for Hovione in the poster session and meet with one of our experts.

 

HOVIONE POSTERS

Aerodynamic Performance of DPIs versus Process Efficiency: A Necessary Compromise

Filipa M. Maia, Maria Palha, Isabel S. Lopes, Filipe Neves

 

Watch Poster Video at AAPS by Márcio Temtem:

 

Innovative Spray Drying Process for Microencapsulation of Dexamethasone for Controlled Ocular Release

Filipa M. Maia1 , Maria Paiva1 , R. Yamamoto2 , T. Cavanagh2 , Filipe Neves1

1 Hovione PharmaScience S.A., 2 Precision Ocular Ltd.

Bulk Properties Impact on the Performance of Amorphous Solid Dispersions 

Iris Duarte, Rui Ferreira, João Vicente

The Impact of Reprocessing on Typical Physicochemical Attributes and Particle Properties of Spray Dried Kollidon® VA64

Rui Ferreira, Iris Duarte, Márcio Temtem

Particle Engineering through Solvent Precipitation: Batch vs Continuous Operation 

Tiago Porfirio, Iris Duarte, João Vicente

Compaction Simulation of an Amorphous Spray Dried Dispersion

João Henriques, Márcio Temtem, Conrad Winters

Modeling Droplet Dynamic and Thermal Profile of Spray Congealing Technology

Inês Matos, Hugo Lisboa, João Henriques, Márcio Temtem

 

Contact us if you would like to schedule a meeting or to find more about the Hovione posters at AAPS.

Schedule a meeting button | Hovione

 

Our colleague, Adam Neunuebel will be pleased to meet you.

adam-neunuebel-photo

Adam Neunuebel

Head of Business Development

 

       

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026